Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Given this risk, we thought we'd take a look at whether Skye Bioscience (NASDAQ:SKYE) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate ...

Skye Bioscience, Inc., a biotechnology company specializing in treatments for obesity and metabolic disorders, announced the launch of its "Anatomy of Progress" video series, showcasing the ...

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation ...

About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.

Get the latest Skye Bioscience Inc. R (09R.F) stock news and headlines to help you in your trading and investing decisions.

Skye Bioscience, Inc. (NASDAQ:SKYE – Get Free Report)’s stock price rose 24% on Thursday . The company traded as high as $1.81 and last traded at $2.15. Approximately 320,782 shares traded ...

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity Provided by GlobeNewswire May 8, 2025, 8:01:00 PM ...

About Skye Bioscience Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes.

Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion PRESS RELEASE Newsfile May. 15, 2023, 07:00 AM ...

Skye Bioscience, Inc., a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the safety review committee for its Phase 1 clinical ...